Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04530591 · ClinicalTrials.gov registry record
User Acceptability of a Device-Based Opioid Overdose Intervention
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 97
- Enrollment target
NCT04530591: Completed study, sponsored by University of Pennsylvania.
NCT04530591 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 97 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04530591 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 97 participants
- Enrollment target
Study Summary
This pilot study evaluates the needs of opioid users for a device-based intervention for opioid overdoses. The results of this one-time short questionnaire will inform development of a novel naloxone delivery device.
Primary Outcome
We aim to characterize the degree of need for a device-based opioid overdose intervention. These were extracted from the participant survey questions as well as from the words, phrases, and sentences used by participants during the interview.
Interventions
- OTHER Interview
- OTHER Survey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2020-08-25 |
| Est. Completion | 2020-09-15 |
What the finished NCT04530591 record still lists
NCT04530591 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 97 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Interview is the first listed.
NCT04530591 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04530591 about?
NCT04530591 is a clinical study titled "User Acceptability of a Device-Based Opioid Overdose Intervention". This pilot study evaluates the needs of opioid users for a device-based intervention for opioid overdoses. The results of this one-time short questionnaire will inform development of a novel naloxone delivery device.
What is the current status of trial NCT04530591?
This trial is currently completed. The enrollment target is 97 participants. The study started on 2020-08-25. Estimated completion is 2020-09-15.
What interventions are being tested in trial NCT04530591?
The interventions under investigation include: Interview (OTHER), Survey (OTHER).
Who is sponsoring clinical trial NCT04530591?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI